AST SpaceMobile vs. Rocket Lab: Which Space Stock Is a Better Buy in 2026?

AST SpaceMobile and Rocket Lab both posted strong FY 2025 revenue growth, with ASTS up 1,500% to $70.9 million and RKLB up 38% to $601.8 million, but both remain loss-making and capital intensive. The article favors Rocket Lab for 2026, citing its $2.2 billion backlog, 58% backlog contribution from Space Systems, and healthier balance sheet versus ASTS's higher leverage and build-out risk. Near-term catalysts include ASTS's mid-June BlueBird launches and Rocket Lab's Neutron rocket debut.

Analysis

RKLB is the cleaner expression of the space economy because it already has two monetization vectors: launch and manufacturing. That matters second-order because launch is inherently lumpy and binary, while hardware/systems revenue can smooth utilization and improve capital efficiency; in a market that still discounts “space” as one-factor moonshot beta, the diversified backlog should deserve a lower discount rate than ASTS’s single-product execution story.

ASTS has the more explosive optionality, but the market is effectively paying for successful scaling before the operating proof exists. The next launch window is a short-dated catalyst with asymmetric downside: a clean deployment can re-rate confidence quickly, but any anomaly would likely trigger a financing overhang and compress the multiple hard, because this model is still dependent on continuous capital access before meaningful cash generation.

The overlooked dynamic is competitive sequencing. RKLB’s Neutron is the real bridge from “useful niche provider” to “strategic defense/enterprise platform,” which could expand addressable demand beyond small-sat launches if it performs. Meanwhile, ASTS’s commercial path is hostage not just to tech execution but to carrier economics; if coverage works but monetization terms are weak, the equity story can stall even on operational success.

Consensus is still too focused on headline growth rates and not enough on balance-sheet survivability and schedule risk. The market is likely over-penalizing RKLB’s near-term losses relative to ASTS because RKLB’s losses are funding a broader platform with better customer diversification and more visible backlog conversion. On a 6-12 month horizon, RKLB looks like the higher-probability compounder; ASTS remains the more convex, event-driven trade.

Key Decisions for Investors

• Initiate long RKLB vs short ASTS pair trade for 6-12 months; thesis is that backlog quality, manufacturing mix, and lower financing risk should outperform ASTS’s binary launch-driven tape.
• Buy RKLB on any post-news pullback tied to Neutron timing skepticism; target a 3-6 month hold where backlog conversion can re-anchor valuation and limit downside to execution noise.
• For event traders, buy ASTS call spreads into the next launch window only if implied volatility remains below the expected move; this is a catalyst trade, not a core hold.
• Avoid outright shorting ASTS unless launch/deployment risk deteriorates materially; the stock can remain expensive longer than fundamentals allow, but financing risk makes downside fast if the catalyst disappoints.
• If managing sector exposure, overweight RKLB over defense-adjacent space names on the view that dual revenue streams and backlog visibility offer the best risk-adjusted entry point in 2026.